Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 8, Pages 1057-1066Publisher
SPRINGER
DOI: 10.1007/s00262-015-1713-5
Keywords
Peptide vaccines; Immunotherapy; CD8 T cells; Type-I interferon; STING
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R01CA136828, R01CA157303]
- Georgia Regents University Cancer Center
- Georgia Research Alliance (GRA)
- NATIONAL CANCER INSTITUTE [R01CA103921, R01CA157303, R01CA136828] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Therapeutic vaccines to induce anti-tumor CD8 T cells have been used in clinical trials for advanced melanoma patients, but the clinical response rate and overall survival time have not improved much. We believe that these dismal outcomes are caused by inadequate number of antigen-specific CD8 T cells generated by most vaccines. In contrast, huge CD8 T cell responses readily occur during acute viral infections. High levels of type-I interferon (IFN-I) are produced during these infections, and this cytokine not only exhibits anti-viral activity but also promotes CD8 T cell responses. The studies described here were performed to determine whether promoting the production of IFN-I could enhance the potency of a peptide vaccine. We report that cyclic diguanylate monophosphate (c-di-GMP), which activates the stimulator of interferon genes, potentiated the immunogenicity and anti-tumor effects of a peptide vaccine against mouse B16 melanoma. The synergistic effects of c-di-GMP required co-administration of costimulatory anti-CD40 antibody, the adjuvant poly-IC, and were mediated in part by IFN-I. These findings demonstrate that peptides representing CD8 T cell epitopes can be effective inducers of large CD8 T cell responses in vaccination strategies that mimic acute viral infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available